Zentrum für Urologie Zürich - pd-dr-med-thomas-hermanns

Publikationen

1. Original Articles (peer reviewed)

Impact factors (IF) according to the latest Journal Citation Reports^®Science Edition 2020

Brook GA, Houweling DA, Gieling RG, Hermanns T, Joosten EA, Bär DP, Gispen WH, Schmitt AB, Leprince P, Noth J, Nacimiento W (2000)
Attempted endogenous tissue repair following experimental spinal cord injury in the rat: involvement of cell adhesion molecules L1 and N-CAM?
Eur J Neurosci. 12(9): 3224-38
Impact Factor: 3.386
Hermanns T, Sulser T, Fatzer M, Baumgartner MK, Rey JM, Sigrist MW, Seifert HH (2009)
Laser fibre deterioration and loss of power output during photo-selective 80-W potassium-titanyl-phosphate laser vaporisation of the prostate.
Eur Urol. 55(3): 679-85
Impact factor: 20.096
Baumgartner MK, Hermanns T, Cohen A, Schmid DM, Seifert B, Sulser T, Strebel
RT (2008)
Patient’s knowledge about risk factors for erectile dysfunction is poor.
J Sex Med. 5(10): 2399-404
Impact factor: 3.802
Sørensen KD, Wild PJ, Mortezavi A, Adolf K, Tørring N, Heebøll S, Ulhøi BP, Ottosen P, Sulser T, Hermanns T, Moch H, Borre M, Ørntoft TF, Dyrskjøt L (2009)
Genetic and epigenetic SLC18A2 silencing in prostate cancer is an independent adverse predictor of biochemical recurrence after radical prostatectomy.
Clin Cancer Res. 15(4): 1400-10
Impact factor: 12.531
Hermanns T, Sauermann P, Rufibach K, Frauenfelder T, Sulser T, Strebel RT (2009)
Is there a role for Tamsulosin in the treatment of distal ureteral stones of 7mm or less? Results of a randomised, double-blind, placebo-controlled trial.
Eur Urol. 56(3): 407-12
Impact factor: 20.096
Wild PJ, Fuchs T, Stoehr R, Zimmermann D, Frigerio S, Padberg B, Steiner I, Zwarthoff EC, Burger M, Denzinger S, Hofstaedter F, Kristiansen G, Hermanns T, Seifert HH, Provenzano M, Sulser T, Roth V, Buhmann JM, Moch H, Hartmann A (2009)
Detection of urothelial bladder cancer cells in voided urine can be improved by a combination of cytology and standardized microsatellite analysis.
Cancer Epidemiol Biomarkers Prev. 18(6): 1798-806
Impact factor: 4.254
Tischler V, Fritzsche R, Wild PJ, Stefan C, Seifert HH, Riener MO, Hermanns T, Gerhardt J, Schraml P, Jung K, Moch H, Soltermann A, Kristiansen G (2010)
Periostin is up-regulated in high grade and high stage prostate cancer.
BMC Cancer. 10: 273-81
Impact factor: 3.288
Ikenberg K, Fritzsche FR, Zuerrer-Haerdi U, Hofmann I, Hermanns T, Seifert H, Müntener M, Provenzano M, Sulser T, Behnke S, Gerhardt J, Mortezavi A, Wild P, Hofstädter F, Burger M, Moch H, Kristiansen G (2010)
Insulin-like growth factor II mRNA binding protein 3 (IMP3) is overexpressed in prostate cancer and correlates with higher Gleason scores.
BMC Cancer. 10: 341-6
Impact factor: 4.430
Mortezavi A, Hermanns T, Seifert HH, Baumgartner MK, Provenzano M, Sulser T, Burger M, Hofstädter F, Krek W, Hartmann A, Moch H, Kristiansen G, Wild PJ (2011)
KPNA2 expression is an independent adverse predictor of biochemical recurrence after radical prostatectomy.
Clin Cancer Res. 17(5): 1111-21
Impact factor: 12.531
Gerhardt J, Steinbrech C, Büchi O, Behnke S, Bohnert A, Fritzsche FR, Wild PJ, Schraml P, Hermanns T, Müntener M, Kristiansen G (2011)
The androgen-regulated calcium-activated nucleotidase 1 is strongly overexpressed in prostate cancer and is tumorbiologically relevant in vitro.
Am J Pathol. 178(4): 1847-60
Impact factor: 4.307
Hermanns T, Strebel DD, Hefermehl LJ, Gross O, Mortezavi A, Müller A, Eberli D,
Müntener M, Michel MS, Meier AH, Sulser T, Seifert HH (2011)
Lithium triborate-laser vaporisation of the prostate using the 120W, high performance system laser: high performance all the way?
J Urol. 185(6): 2241-7
Impact factor: 7.450
Beer M, Montani M, Gerhardt J, Wild PJ, Hany T, Hermanns T, Müntener M, Kristiansen G (2012)
Profiling gastrin releasing peptide receptor in prostate tissues: clinical implications and molecular correlates.
Prostate. 72(3): 318-25
Impact factor: 4.014
Von Boehmer L, Keller L, Mortezavi A, Provenzano M, Sais G, Hermanns T, Sulser T, Jungbluth AA, Old LJ, Kristiansen G, van den Broek M, Moch H, Knuth A, Wild PJ (2011)
MAGE-C2/CT10 protein expression is an independent predictor of recurrence in prostate cancer.
PLoS One. 6(7); e21366
Impact factor: 3.240
Gerhardt J, Montani M, Wild PJ, Beer M, Huber F, Hermanns T, Müntener M, Kristiansen G (2012)
FoxA1 promotes tumor progression in prostate cancer and represents a novel hallmark of castrate resistant prostate cancer.
Am J Pathol. 180(2): 848-61
Impact factor: 4.307
Beermann A, Ghanjati F, Hermanns T, Poyet C, Fischer PJ, Wernet P, Santourlidis S (2011)
Methods for Separate Isolation of Cell-Free DNA and Cellular DNA from Urine-Application of Methylation-Specific PCR on both DNA Fractions
The Open Biomarker J. 4: 15-17
Impact factor: n/a
Mortezavi A, Hermanns T, Seifert HH, Wild PJ, Schmid DM, Sulser T, Eberli D (2012)
Intrafascial dissection significantly increases positive surgical margin and biochemical recurrence rates after robotic assisted radical prostatectomy.
Urol Int. 26: 17-24
Impact factor: 2.089
Boysen G, Bausch-Fluck D, Thoma CR, Novicka AM, Stiehl DP, Cima IL, Luu V, von Teichman A, Hermanns T, Sulser T, Ingold-Heppner B, Fankhauser N, Wenger RH, Krek W, Schraml P, Wollscheid B, Moch H (2012)
Relative quantification of the renal carcinoma surfaceome reveals pVHL-dependent cell surface glycoproteins as clinical markers.
Neoplasia. 14(6): 535-46
Impact factor: 5.715
Montani M, Hermanns T, Müntener M, Wild P, Sulser T, Kristiansen G (2013)
Multidrug resistance protein 4 (MRP4) expression in prostate cancer is associated with androgen signalling and decreases with tumor progression.
Virchows Arch. 463(1): 437-46
Impact factor: 4.064
Kaufmann MR, Schraml P, Hermanns T, Wenger RH, Camenisch G (2013)
Onconeuronal antigen Cdr2 correlates with HIF prolyl-4-hydroxylase PHD1 and worse prognosis in renal cell carcinoma.
Exp Mol Pathol. 94(3): 453-457
Impact factor: 3.362
Mortezavi A, Hermanns T, Hefermehl LJ, Spahn D, Seifert B, Weber DR, Schmid DM, Sulser T, Eberli D (2013)
Continuous anti-platelet therapy in robotic-assisted laparoscopic radical prostatectomy.
J Laparoendosc Adv Surg Tech A. 23(6): 500-5
Impact factor: 1.878
Dannenmann SR, Thielicke J, Stöckli M, Matter C, von Boehmer L, Cecconi V, Hermanns T, Hefermehl L, Schraml PH, Moch H, Knuth A, van den Broek M (2013)
Tumor-associated macrophages subvert T-cell function and correlate with reduced survival in clear cell renal cell carcinoma.
Oncoimmunology. 2(3): e23562
Impact factor: 8.110
Hermanns T, Fankhauser CD, Hefermehl, LJ, Kranzbühler B, Wong LM, Capol JC, Zimmermann M, Sulser T, Müller A (2013)
Prospective evaluation of irrigation fluid absorption during pure transurethral bipolar plasma vaporisation of the prostate using expired breath ethanol measurements.
BJU Int. 112(5): 647-54
Impact factor: 5.588
Kranzbühler B, Wettstein MS, Fankhauser CD, Grossmann NC, Gross O, Poyet C, Largo R, Fischer B, Zimmermann M, Sulser T, Müller A, Hermanns T (2013)
Pure bipolar plasma vaporization of the Prostate: The Zürich experience.
J Endourol. 27(10): 1261-6
Impact factor: 2.942
Hefermehl LJ, Largo R, Hermanns T, Poyet C, Sulser T, Eberli D (2013)
Lateral temperature spread of monopolar, bipolar and ultrasonic instruments for robotic assisted laparoscopic surgery.
BJU Int. 114(2): 245-52
Impact factor: 5.588
Hermanns T, Gross O, Kranzbühler B, Hefermehl LJ, Poyet C, Fankhauser CD, Müller A, Yap SA, Michel MS, Eberli A, Müntener M, Zimmermann M, Sulser T, Seifert HH (2013)
Ablative efficiency of 532 nm laser vaporization compared to transurethral resection of the prostate: Results from a prospective three-dimensional ultrasound volumetry study.
World J Urol. 32(5): 1267-74
Impact factor: 4.226
Poyet C, Jentsch B, Hermanns T, Schweckendieck D, Seifert HH, Schmidtpeter M, Sulser T, Moch H, Wild PJ, Kristiansen G (2014)
Expression of histone deacetylases 1, 2 and 3 in urothelial bladder cancer.
BMC Clin Pathol. 14(1): 10
Impact factor: n/a
Dannenmann SR, Hermanns T, Bransi A, Matter C, von Boehmer L, Stevanovic S, Schraml PH, Moch H, Knuth A, van den Broek M (2013)
Spontaneous peripheral T cell responses towards the tumor-associated antigen Cyclin D1 in patients with clear cell renal cell carcinoma.
Cancer Immunol Res. 1(5): 288-95
Impact factor: 11.151

Templeton AJ, Ace O, McNamara MG, Al-Mubarak M, Vera-Badillo FE, Hermanns T, Šeruga B, Ocaña A, Tannock IF, Amir E (2014)
Prognostic Role of Platelet to Lymphocyte Ratio in Solid Tumors: A Systematic Review and Meta-Analysis.
Cancer Epidemiol Biomarkers Prev. 23(7): 1204-12
Impact factor: 4.254
Hermanns T, Bhindi B, Wei Y, Yu J, Noon AP, Richard PO, Bhatt JR, Almatar A, Jewett MAS, Fleshner NE, Zlotta AR, Templeton AJ, Kulkarni GS (2014)
Pretreatment neutrophil-to-lymphocyte ratio as predictor of adverse outcomes in patients undergoing radical cystectomy for urothelial carcinoma of the bladder.
Br J Cancer. 111(3): 444-51
Impact factor: 7.640
Hermanns T, Grossmann NC, Wettstein MS, Fankhauser CD, Capol JC, Poyet C, Hefermehl LJ, Zimmermann M, Sulser T, Müller A (2015)
Absorption of irrigation fluid occurs frequently during high-power 523nm laser vaporization of the prostate.
J Urol. 193(1): 211-6
Impact factor: 7.450
Ghanjati F, Beermann A, Hermanns T, Poyet C, Araúzo-Bravo MJ, Seifert HH, Schmidtpeter M, Goering W, Sorg R, Wernet P, Santourlidis S (2014)
Unreserved application of epigenetic methods to define differences of DNA methylation between urinary cellular and cell-free DNA.
Cancer Biomark. 14(5): 295-302
Impact factor: 4.388
Liu Y, Noon AP, Cabeza EA, Shen J, Kukc , Ilczynski C, Ni R, Sukhu B, Chan K, Barbosa-Morais NL, Hermanns T, Blencowe BJ, Azad A, van der Kwast TH, Catto JWF, Zlotta AR, Wrana JL (2014)
Next generation RNA sequencing of archival formalin fixed paraffin embedded urothelial bladder cancer.
Eur Urol. 66(6): 982-6
Impact factor: 20.096
Richard PO, Abramsky H, Bhatt JR, Hermanns T, Hersey KM, Chadwick K, Habeeba B Fleshner NE (2015)
Impact of energy drinks on androgen deprivation induced fatigue: Results of a pilot study
J Caffeine Res. 5(1): 50-4
Impact factor: n/a
Ruf M, Fieger C, Hartmann A, Hermanns T, Poyet C, van den Broek M, Sulser T, Moch H, Schraml P (2015)
CD70 is upregulated via the pVHL-HIFα axis and triggers the release of the soluble form of its receptor CD27 from tumour infiltrating lymphocytes in renal cell carcinoma.
Clin Cancer Res. 21(4): 889-98
Impact factor: 12.531
Richard PO, Bhatt JR, Hermanns T, Juvet T, Manickavachagam K, Evans AJ, Kachura JR, Jewett MAS, Finelli A (2015)
The Outcome of Renal Tumor Biopsies for Small Renal Masses: A Single-Center 13-year Experience.
Eur Urol. 68(6): 1007-13
Impact factor: 20.096
Nayan M, Bhindi B, Yu JL, Hermanns T, Hamilton RJ, Finelli A, Jewett MAS, Zlotta AR, Fleshner NE, Kulkarni GS (2015)
The impact of metformin on cancer-specific survival outcomes in diabetic patients undergoing radical cystectomy for urothelial carcinoma of the bladder.
Urol Oncol – Semin Ori. 33(9): 386 e7-13
Impact factor: 3.498
Benoit T, Keller E, Wolfsgruber P, Hermanns T, Günthart M, Banzola I, Sulser T, Provenzano M, Poyet C (2015)
High VEGF-D and low MMP-2 serum levels predict nodal positive disease in invasive bladder cancer.
Med Sci Monit. 21: 2266-74
Impact factor: 2.649
Poyet C, Buser L, Roudnicky F, Detmar M, Hermanns T, Mannhard D, Höhn A, Sulser T, Moch H, Wild PJ (2015)
Connexin 43 expression predicts poor progression-free survival in patients with non-muscle invasive urothelial bladder cancer.
J Clin Pathol. 68(10): 819-24
Impact factor: 3.411
Poyet C, Nieboer D, Bhindi B, Kulkarni GS, Wiederkehr C, Largo R, Wild PJ, Sulser T, Hermanns T (2016)
Prostate cancer risk prediction using the updated ERSPC and PCPT risk calculators: Independent validation and comparison in a contemporary European cohort.
BJU Int. 117(3): 401-8
Impact factor: 5.588
Wettstein MS, Buser L, Hermanns T, Roudnicky F, Eberli D, Baumeister P, Sulser T, Wild P, Poyet C (2015)
CD73 predicts favourable prognosis in patients with non-muscle invasive urothelial bladder cancer.
Dis Markers. 2015: 785461
Impact factor: 3.434
Bhindi B, Hermanns T*, Wei Y, Yu J, Templeton AJ, Richard PO, Wettstein MS, Shirdhar SS, Jewett MAS, Fleshner NE, Zlotta AR, Kulkarni GS (2016)
How to best use the complete blood count to predict oncologic outcomes following radical cystectomy for bladder cancer.
Br J Cancer. 114(2): 207-12
Impact factor: 7.640
Mortezavi A, Sulser T, Robbiani J, Drescher E, Disteldorf D, Eberli D, Poyet C, Baumgartner MK, Seifert HH, Hermanns T (2016)
Long-term oncological outcome of an initial series of laparoscopic radical prostatectomy for clinically localized prostate cancer after a median follow-up of 10 years.
Clin Genitourin Cancer. 14(4):290-7
Impact factor: 2.872
Poyet C, Hermanns T, Zhong Q, Eberli D, Burger M, Hofstaedter F, Hartmann A, Stöhr R. Zwarthoff EC, Sulser T, Wild PJ (2015)
Positive FGFR3 immunoreactivity defines low-grade urothelial bladder cancer.
Oncol Lett. 10(5): 2753-60
Impact factor: 2.967
Wettstein MS, Poyet C, Grossmann NC, Fankhauser CD, Keller XE, Kozomara M, Meyer S, Sulser T, Müller A, Hermanns T (2016)
Absorption of irrigation fluid during XPS™ GreenLight laser vaporization of the prostate: results from a prospective breath ethanol monitoring study.
World J Urol. Epub. ahead of print
Impact factor: 4.226
Santourlidis S, Ghanjati F, Beermann A, Hermanns T, Poyet C (2016)
IDLN-MSP - Idiolocal normalization of real-time methylation-specific PCR for genetic
imbalanced DNA specimens.
BioTechniques. 60(2): 84-7
Impact factor: 1.993
Nayan M, Bhindi B, Yu JL, Mamdani M, Fleshner NE, Hermanns T, Chung P, Milosevic M, Bristow R, Warde P, Hamilton RJ, Finelli A, Jewett MAS, Zlotta AR, Shridhar SS, Kulkarni GS (2016)
The initiation of a multidisciplinary bladder cancer clinic and the uptake of neoadjuvant chemotherapy: A time-series analysis.
Can Urol Assoc J. 10(1-2): 25-30
Impact factor: 1.862
Mortezavi A, Keller EX, Poyet C, Hermanns T, Saba K, Randazzo M, Fankhauser CD, Wild PJ, Moch H, Sulser T, Eberli D (2016)
Clinical impact of prostate biopsy undergrading in an academic and community setting.
World J Urol. 34(10):1481-90
Impact factor: 4.226
Templeton AJ, Knox JJ, Lin X, Simantov R, Xie W, Mitchell N, Broom R, Fay AP, Rini B, Donskov F, Bjarnason GA, Smoragiewicz M, Kollmannsberger C, Kanesvaran R, Alimohamed N, Hermanns T, Wells C, Amir E, Choueiri TK, Heng DYC (2016)
Change in neutrophil to lymphocyte ratio in response to targeted therapy for metastatic renal cell carcinoma as a prognosticator and biomarker of efficacy.
Eur Urol. 70(2):358-64.
Impact factor: 20.096
Fankhauser CD, Bode PK, Hermanns T, Sander S, Sulser T, Altevogt P, Moch H, Tischler V (2016)
L1-CAM is commonly expressed in testicular germ cell tumors.
J Clin Pathol. 69(5):460-2.
Impact factor: 3.411
Poyet C, Wettstein MS, Lundon DJ, Bhindi B, Kulkarni GS, Saba K, Sulser T, Vickers AJ, Hermanns T (2016)
External evaluation of a novel prostate cancer risk calculator (ProstateCheck) based on data of the Swiss arm of the ERSPC.
J Urol. 196(5): 1402-7
Impact factor: 7.450
Kranzbühler B, Gross O, Fankhauser CD, Wettstein MS, Grossmann NC, Hefermehl LJ, Zimmermann M, Müller A, Eberli D, Sulser T, Poyet C, Hermanns T (2016)
Prostate volume reduction following pure transurethral bipolar plasma vaporization and conventional transurethral resection of the prostate: a prospective investigation using transrectal 3D ultrasound volumetry.
World J Urol. 35(3):429-435
Impact factor: 4.226
Wettstein MS, Saba K, Umbehr MH, Fankhauser CD, Adank JP, Hofmann M, Murtola T Sulser T, Hermanns T, Wild PJ, Poyet C (2017)
Prognostic role of preoperative serum lipid levels in patients undergoing radical prostatectomy for clinically localized prostate cancer.
Prostate. 77(5):549-556
Impact factor: 4.104
Olkhov-Mitsel E, Savio AJ, Kron KJ, Pethe VV, Hermanns T, Fleshner NE, van Rhijn B, van der Kwast TH, Zlotta AR, Bapat B (2017)
Epigenome-wide DNA methylation profiling identifies differential methylation biomarkers in high grade bladder cancer.
Transl Oncol. 10(2):168-177
Impact factor: 4.243
Corro C, Hejhal T, Poyet C, Sulser T, Hermanns T, Winder T, Prager G, Wild PJ, Frew I, Moch H, Rechsteiner M (2017)
Detecting circulating tumor DNA in renal cancer: An open challenge.
Exp Mol Pathol. 102(2):255-261
Impact factor: 3.362
Zong Q, Guo T, Rechsteiner M, Ru?schoff JH, Rupp N, Fankhauser C, Saba K, Mortezavi A, Poyet C, Hermanns T, Zhu Y, Moch H, Aebersold R, Wild PJ (2017)
A comprehensive collection of tissue microarray images and clinical outcome data of prostate cancer patients.
Sci Data. 4:170014
Impact factor: 6.444
Kulkarni GS, Hermanns T*, Wei Y, Bhindi B, Satkunasivam R, Athanasopoulos P, Bostrom PJ, Kuk C, Li K, Templeton AJ, Sridhar SS, van der Kwast TH, Chung P, Bristow RG, Milosevic M, Warde P, Fleshner NE, Jewett MAS, Bashir S, Zlotta AR (2017)
Propensity Score Analysis of Radical Cystectomy Versus Bladder-Sparing Trimodal Therapy in the Setting of a Multidisciplinary Bladder Cancer Clinic.
J Clin Oncol. 35(20):2299-2305
Impact factor: 44.544
Mortezavi A, Salemi S, Rupp N, Rueschoff JH, Hermanns T, Poyet C, Randazzo M, Simon HU, Moch H, Sulser T, Wild PJ, Eberli D (2017)
Negative LC3b immunoreactivity in cancer cells is an independent prognostic predictor of prostate cancer specific death.
Oncotarget. 8(19):31765-31774
Impact factor: 5.168
Bezan A, Posch F, Ploner F, Bauernhofer T, Pichler M, Szkandera J, Hutterer GC, Pummer K, Gary T, Samonigg H, Beyer J, Winder T, Hermanns T, Fankhauser CD, Gerger A, Stotz M (2017)
Risk stratification for venous thromboembolism in patients with testicular germ cell tumors.
PloS one. 12(4):e0176283
Impact factor: 3,240
Bhindi B, Fleshner NE, Finelli A, Hamilton RJ, Hermanns T, Toi A, Poyet C, Zlotta AR, Jiang H, Evans A, van der Kwast T, Li K, Kulkarni GS (2017)
Creation and internal validation of a biopsy avoidance prediction tool to aid in the choice of diagnostic approach in patients with prostate cancer suspicion.
Urol Oncol – Semin Ori. 35(10):604.e17-604.e24
Impact factor: 3.498
Mannil M, von Spiczak J, Hermanns T, Alkadhi H, Fankhauser CD (2017)
Prediction of successful shock wave lithotripsy with CT: a phantom study using texture analysis.
Abdom Radiol (NY). 43(6):1432-1438
Impact factor: 3.039
Fankhauser CD, Sander S, Roth L, Beyer J, Hermanns T (2018)
Improved survival in metastatic germ-cell cancer.
Ann Oncol. 29(2):347-351
Impact factor: 32.976
Erichsen L, Ghanjati F, Beermann A, Poyet C, Hermanns T, Schulz WA, Seifert HH, Wild PJ, Buser L, Kröning A, Braunstein S, Anlauf M, Jankowiak S, Hassan M, Bendhack ML, Bravo MA, Santourlidis S (2018)
Aberrant methylated key genes of methyl group metabolism within molecular etiology of urothelial carcinogenesis.
Sci Rep. 22;8(1):3477
Impact factor: 4.379
Mortezavi A, Märzendorfer O, Donati OF, Rizzi G, Rupp NJ, Wettstein MS, Gross O, Sulser T, Hermanns T, Eberli D (2018)
Diagnostic accuracy of mpMRI and fusion-guided targeted biopsy evaluated by transperineal template saturation prostate biopsy for the detection and characterization of prostate cancer.
J Urol. 200(2):309-318
Impact factor: 7.450
Fankhauser CD, Sander S, Roth L, Gross O, Eberli D, Sulser T, Seifert B, Beyer J, Hermanns T. (2018)
Systemic inflammatory markers have independent prognostic value in patients with metastatic testicular germ cell tumours undergoing first-line chemotherapy.
Br J Cancer. 118(6):825-830
Impact factor: 7.640
Fankhauser CD, Schüffler PJ, Gillessen S, Omlin A, Rupp NJ, Rueschoff JH, Hermanns T, Poyet C, Sulser T, Moch H, Wild PJ (2017)
Comprehensive immunohistochemical analysis of PD-L1 shows scarce expression in castration-resistant prostate cancer.
Oncotarget. 9(12):10284-10293
Impact factor: 5.168
Mannil M, von Spiczak J, Hermanns T, Poyet C, Alkadhi H, Fankhauser CD (2018)
Three-Dimensional texture analysis with machine learning provides incremental predictive information for successful shock wave lithotripsy in patients with kidney stones.
J Urol. 200(4):829-836
Impact factor: 7.450
Fankhauser CD, Mohebbi N, Grogg J, Holenstein A, Zhong Q, Hermanns T, Sulser T, Steurer J, Poyet C (2018)
Prevalence of hypertension and diabetes after exposure to extracorporeal shock-wave lithotripsy in patients with renal calculi: a retrospective non-randomized data analysis.
Int Urol Nephrol. 50(7):1227-1233
Impact factor: 2.370
Hermanns T, Grossmann NC, Wettstein MS, Keller EX, Fankhauser CD, Gross O, Kranzbühler B, Lüscher M, Meier AH, Sulser T, Poyet C (2019)
Is loss of power output due to laser fiber degradation still an issue during prostate vaporization using the 180 W GreenLight XPS laser?
World J Urol. 37(1):181-187
Impact factor: 4.226
Fankhauser CD, Hermanns T, Lieger L, Diethelm O, Umbehr M, Luginbühl T, Sulser T, Müntener M, Poyet C (2018)
Extracorporeal shock wave lithotripsy versus flexible ureterorenoscopy in the treatment of untreated renal calculi.
Clin Kidney J. 11(3):364-369
Impact factor: 4,452
Arvaniti E, Fricker KS, Moret M, Rupp N, Hermanns T, Fankhauser C, Wey N, Wild PJ, Rüschoff JH, Claassen M (2018)
Automated Gleason grading of prostate cancer tissue microarrays via deep learning.
Sci Rep. 8(1):12054
Impact factor: 4.379
Leão R, Lee D, Figueiredo A, Hermanns T, Wild P, Komosa M, Lau I, Mistry M, Nunes NM, Price AJ, Zhang C, Lipman T, Poyet C, Valtcheva N, Oehl K, Coelho H, Sayyid R, Gomes AM, Prado E Castro L, Sweet J, Vinagre J, Apolónio J, Stephens D, Faleiro I, Fadaak K, Richard PO, Kulkarni G, Zlotta AR, Hamilton RJ, Castelo-Branco P, Tabori U (2019)
Combined genetic and epigenetic alterations of the TERT promoter affect clinical and biological behaviour of bladder cancer.
Int J Cancer. 144(7):1676-1684
Impact factor: 7.396
Lee DD, Leão R, Komosa M, Gallo M, Zhang CH, Lipman T, Remke M, Heidari A, Nunes NM, Apolónio JD, Price AJ, De Mello RA, Dias JS, Huntsman D, Hermanns T, Wild PJ, Vanner R, Zadeh G, Karamchandani J, Das S, Taylor MD, Hawkins CE, Wasserman JD, Figueiredo A, Hamilton RJ, Minden MD, Wani K, Diplas B, Yan H, Aldape K, Akbari MR, Danesh A, Pugh TJ, Dirks PB, Castelo-Branco P, Tabori U (2019)
DNA hypermethylation within TERT promoter upregulates TERT expression in cancer.
J Clin Invest.129(4):1801
Impact factor: 14.808
Keller EX, Bachofner J, Britschgi AJ, Saba K, Mortezavi A, Kaufmann B, Fankhauser CD, Wild P, Sulser T, Hermanns T, Eberli D, Poyet C (2018)
Prognostic value of unifocal and multifocal positive surgical margins in a large series of robot-assisted radical prostatectomy for prostate cancer.
World J Urol. 37(9):1837-44
Impact factor: 4.226
Tan WS, Ahmad A, Feber A, Mostafid H, Cresswell J, Fankhauser CD, Waisbrod S, Hermanns T, Sasieni P, Kelly JD; DETECT I trial collaborators. (2019)
Development and validation of a haematuria cancer risk score to identify patients at risk of harbouring cancer.
J Intern Med. 285(4):436-445
Impact factor: 8.989
Hermanns T, Gross O, Fankhauser CD, Wettstein MS, Grossmann NC, Keller EX,
Eberli D, Sulser T, Poyet C, Kranzbühler B (2019)
Pure bipolar plasma vaporization of the prostate: 3-year results combining clinical mid-term outcome and 3D ultrasound volumetry data.
J Endourol. 33(2):107-112
Impact factor: 2.942
Bihr S, Ohashi R, Moore A, Ru?schoff J, Beisel C, Hermanns T, Mischo A, Corro C, Beyer J, Beerenwinkel J, Moch H, Schraml P (2019)
Expression and mutation patterns of PBRM1, BAP1 and SETD2 mirror specific
evolutionary subtypes in clear cell Renal Cell Carcinoma.
Neoplasia. 21(2):247-256.
Impact factor: 5.715
Fankhauser CD, Gerke TA, Roth L, Sander S, Grossmann NC, Kranzbühler B, Eberli D, Sulser T, Beyer J, Hermanns T (2019)
Pre-orchiectomy tumor marker levels should not be used for International Germ Cell Consensus Classification (IGCCCG) risk group assignment.
J Cancer Res Clin Oncol. 145(3):781-85
Impact factor: 4.553
Schraml P, Athelogou M, Hermanns T, Huss R, Moch H (2019)
Specific immune cell and lymphatic vessel signatures identified by image analysis in renal cancer.
Mod Pathol. 32(7):1042-52
Impact factor: 7.842
Dieckmann KP, Radtke A, Geczi L, Matthies C, Anheuser P, Eckardt U, Sommer J, Zengerling F, Trenti E, Pichler R, Belz H, Zastrow S, Winter A, Melchior S, Hammel J, Kranz J, Bolten M, Krege S, Haben B, Loidl W, Ruf CG, Heinzelbecker J, Heidenreich A, Cremers JF, Oing C, Hermanns T, Fankhauser CD, Gillessen S, Reichegger H, Cathomas R, Pichler M, Hentrich M, Eredics K, Lorch A, Wülfing C, Peine S, Wosniok W, Bokemeyer C, Belge G (2019)
Serum Levels of MicroRNA-371a-3p (M371 Test) as a New Biomarker of Testicular Germ Cell Tumors: Results of a Prospective Multicentric Study.
J Clin Oncol. 37(16):1412-23
Impact factor: 44.544
Wettstein MS, Rooprai JK, Pazhepurackel C, Wallis CJD, Klaassen Z, Uleryk EM, Hermanns T, Fleshner NE, Zlotta AR, Kulkarni GS (2019)
Systematic review and meta-analysis on trimodal therapy versus radical cystectomy for muscle-invasive bladder cancer: Does the current quality of evidence justify definitive conclusions?
PLoS One. 29;14(4)
Impact factor: 3.240
Wettstein MS, Pazhepurackel C, Neumann AS, Woon DTS, Herrera-Caceres JO, Kozomara M, Poyet C, Sulser T, Kulkarni GS, Hermanns T (2019)
Photoselective vaporization of the prostate: study outcomes as a function of risk of bias, conflicts of interest and industrial sponsorship
World J Urol. 38(3):741-746
Impact factor: 4.226
Shao W, Guo T, Toussaint NC, Xue P, Wagner U, Li L, Charmpi K, Zhu Y, Wu J, Buljan M, Sun R, Rutishauser D, Hermanns T, Fankhauser CD, Poyet C, Ljubicic J, Rupp N, Rüschoff JH, Zhong Q, Beyer A, Ji J, Collins BC, Liu Y, Rätsch G, Wild PJ, Aebersold R. (2019)
Comparative analysis of mRNA and protein degradation in prostate tissues indicates high stability of proteins
Nat Commun. 10(1):2524
Impact factor: 14.919
Kranzbühler B, Salemi S, Umbricht CA, Deberle LM, Müller C, Burger IA, Hermanns T, Sulser T, Eberli D (2019)
Concentration-dependent effects of dutasteride on prostate-specific membrane antigen (PSMA) expression and uptake of 177 Lu-PSMA-617 in LNCaP cells
Prostate. 79(12):1450-1456
Impact factor: 4.104
Hench IB, Cathomas R, Costa L, Fischer N, Gillessen S, Hench J, Hermanns T, Kremer E, Mingrone W, Mestre RP, Püschel H, Rothermundt C, Ruiz C, Tolnay M, Burg PV, Bubendorf L, Vlajnic T, Sakk SGFCCR. (2019)
Analysis of AR/ARV7 Expression in Isolated Circulating Tumor Cells of Patients with Metastatic Castration-Resistant Prostate Cancer (SAKK 08/14 IMPROVE Trial)
Cancers (Basel). 11(8):1099
Impact factor: 6.639
Fankhauser CD, Roth L, Grossmann NC, Kranzbühler B, Eberli D, Sulser T, Moch H, Bode PK, Beyer J, Hermanns T. (2019)
CXCL12 expression is an adverse predictor for disease recurrence in patients with metastatic non-seminomatous testicular germ cell tumors
BMC Cancer 14;19(1):802
Impact factor: 4.430
Ferraro DA, Muehlematter UJ, Garcia Schüler HI, Rupp NJ, Huellner M, Messerli M, Rüschoff JH, Ter Voert EEGW, Hermanns T, Burger IA (2019)
68 Ga-PSMA-11 PET has the potential to improve patient selection for extended pelvic lymph node dissection in intermediate to high-risk prostate cancer
Eur J Nucl Med Mol Imaging. 47(1):147-159
Impact factor: 9.236
Schmid FA, Wettstein MS, Kessler TM, Hermanns T, Boss A, Hötker AM, Eberli D (2019)
Contrast media kinetics in multiparametric magnetic resonance imaging before radical prostatectomy predicts the probability of postoperative incontinence
World J Urol. 38(7):1741-48
Impact factor: 4.226
Grogg JB, Schneider K, Bode PK, Wettstein MS, Kranzbühler B, Eberli D, Sulser T, Beyer J, Hermanns T, Fankhauser CD (2019)
A Systematic Review of Treatment Outcomes in Localised and Metastatic Spermatocytic Tumors of the Testis
J Cancer Res Clin Oncol. 145(12):3037-45
Impact factor: 4.553
Lebentrau S, Wolff I, Hempel MC, Haccius M, Kluth LA, Pycha A, Brookman-May S, Schneider TR, Hermanns T, Distler FA, Boegemann M, Kübler H, Shariat SF, Burger M, May M (2019)
Knowledge of German-speaking urologists regarding the association between penile cancer and human papilloma virus: results of a survey of the European PROspective Penile Cancer Study (E-PROPS)
Aktuelle Urol doi: 10.1055
Impact factor: 0.658
Tran B, Ruiz-Morales JM, Gonzalez-Billalabeitia E, Patrikidou A, Amir E, Seidel C, Bokemeyer C, Fankhauser C, Hermanns T, Rumyantsev A, Tryakin A, Brito M, Fléchon A, Kwan EM, Cheng T, Castellano D, Garcia Del Muro X, Hamid AA, Ottaviano M, Palmieri G, Kitson R, Reid A, Heng DYC,
Bedard PL (2020)
Large retroperitoneal lymphadenopathy and increased risk of venous thromboembolism in patients receiving first-line chemotherapy for metastatic germ cell tumors: A study by the global germ cell cancer group (G3)
Cancer Med. 9(1):116-24
Impact factor: 4.452
Ferraro DA, Garcia Schüler HI, Muehlematter UJ, Eberli D, Müller J, Müller A, Gablinger R, Kranzbühler H, Omlin A, Kaufmann PA, Hermanns T*, Burger IA (2020)
Impact of 68 Ga-PSMA-11 PET staging on clinical decision-making in patients with intermediate or high-risk prostate cancer
Eur J Nucl Med Mol Imaging. 47(3):652-664
Impact factor: 9.236
Fankhauser CD, Grogg JB, Hayoz S, Wettstein MS, Dieckmann KP, Sulser T, Bode PK, Clarke NW, Beyer J, Hermanns T (2020)
Risk Factors and Treatment Outcomes of 1,375 Patients with Testicular Leydig Cell Tumors: Analysis of Published Case Series Data
J Urol. 203(5):949-56.
Impact factor: 7.450
Grogg J, Schneider K, Bode PK, Kranzbühler B, Eberli D, Sulser T, Lorch A, Beyer J, Hermanns T, Fankhauser CD
Sertoli Cell Tumors of the Testes: Systematic Literature Review and Meta-Analysis of Outcomes in 435 Patients
25(7):585-59
Impact factor: 5.025
Hermanns T, Savio AJ, Olkhov-Mitsel E, Mari A, Wettstein MS, Saba K, Bhindi B, Kuk C, Poyet C, Wild PJ, Noon A, Bashir S, Juvet T, Rendon RA, Waltregny D, van der Kwast T, Finelli A, Kulkarni GS, Fleshner NE, Lo K, Bapat B, Zlotta AR (2020)
A noninvasive urine-based methylation biomarker panel to detect bladder cancer and discriminate cancer grade
Urol Oncol Semin Ori 38(6):603.e1-.e7
Impact factor: 3.498
Erichsen L, Seifert HH, Schulz WA, Hoffmann MJ, Niegisch G, Araúzo-Bravo MJ, Bendhack ML, Poyet C, Hermanns T, Beermann A, Hassan M, Theis L, Mahmood W, Santourlidis S (2020)
Basic Hallmarks of Urothelial Cancer Unleashed in Primary Uroepithelium by Interference with the Epigenetic Master Regulator ODC1
Sci Rep. 10(1):3808
Impact factor: 4.379
Wettstein MS, Naimark D, Hermanns T, Herrera-Caceres JO, Ahmad A, Jewett MAS, Kulkarni G (2020)
Required efficacy for novel therapies in BCG-unresponsive non-muscle invasive bladder cancer: Do current recommendations really reflect clinically meaningful outcomes?
Cancer Med. 9(10):3287-96
Impact factor: 4.452
Fankhauser CD, Waisbrod S, Fierz C, Becker AS, Kranzbühler B, Eberli D, Sulser T, Mostafid H, Hermanns T. (2020)
Diagnostic accuracy of ultrasonography, computed tomography, cystoscopy and cytology to detect urinary tract malignancies in patients with asymptomatic hematuria World J Urol. 39(1):97-103.
Impact factor: 4.226
Seidel C, Daugaard G, Nestler T, Tryakin A, Fedyanin M, Fankhauser C, Hermanns T, Aparicio J, Heinzelbecker J, Paffenholz P, Heidenreich A, De Giorgi U, Cathomas R, Lorch A, Fingerhut A, Gayer F, Bremmer F, Giannatempo P, Necchi A, Aurilio G, Casadei C, Tran B, Dieckmann KP, Brito M, Ruf C, Oing C, Bokemeyer C (2020)
Human chorionic gonadotropin-positive seminoma patients: A registry compiled by the global germ cell tumor collaborative group (G3)
Eur J Cancer. 132:127-135
Impact factor: 9.162
Bieri U, Hübel K, Seeger H, Kulkarni GS, Sulser T, Hermanns T, Wettstein MS (2020)
Management of Active Surveillance-eligible Prostate Cancer during Pre-transplantation Work-up of Patients with Kidney Failure: A Simulation Study
Clin J Am Soc Nephrol. 15(6):822-829.
Impact factor: 8.237
Ferraro DA, Rüschoff JH, Muehlematter UJ, Kranzbühler B, Müller J, Messerli M, Husmann L, Hermanns T, Eberli D, Rupp NJ, Burger IA (2020)
Immunohistochemical PSMA expression patterns of primary prostate cancer tissue are associated with the detection rate of biochemical recurrence with 68 Ga-PSMA-11-PET
Theranostics. 10(14):6082-6094
Impact factor: 11.556
Wyvekens N, Valtcheva N, Mischo A, Helmchen B, Hermanns T, Choschzick M, Hötker AM, Rauch A, Mühleisen B, Akhoundova D, Weber A, Moch H, Rupp NJ (2020)
Novel morphological and genetic features of fumarate hydratase deficient renal cell carcinoma in HLRCC syndrome patients with a tailored therapeutic approach
Genes Chromosomes Cancer. 2020 Nov;59(11):611-619
Impact factor: 5.006
Gallo A, Fankhauser C, Hermanns T, Beyer J, Christiansen A, Moch H, Bode PK (2020)
HNF1β is a sensitive and specific novel marker for yolk sac tumor: a tissue microarray analysis of 601 testicular germ cell tumors
Mod Pathol. 33(11):2354-2360
Impact factor: 7.842
Fankhauser CD, Penney KL, Gonzalez-Feliciano AG, Clarke NW, Hermanns T, Stopsack KH, Fiorentino M, Loda M, Mahal B, Gerke TA, Preston MA, Mucci LA (2020)
Inferior Cancer Survival for Men with Localized High-grade Prostate Cancer but Low Prostate-specific Antigen
Eur Urol. 78(4):637-639.
Impact factor: 20.096
Fankhauser CD, Roth L, Kranzbühler B, Eberli D, Bode P, Moch H, Oliveira P, Ramani V, Beyer J, Hermanns T (2020)
The Role of Frozen Section Examination During Inguinal Exploration in Men with Inconclusive Testicular Tumors: A Systematic Review and Meta-analysis
Eur Urol Focus. S2405-4569(20)30185-1
Impact factor: 5.996
Grogg JB, Schneider K, Bode PK, Kranzbühler B, Eberli D, Sulser T, Beyer J, Lorch A, Hermanns T, Fankhauser CD (2020)
Risk Factors and Treatment Outcomes of 239 Patients with Testicular Granulosa Cell Tumors: A Systematic Review of Published Case Series Data
J Cancer Res Clin Oncol. 146(11):2829-2841
Impact factor: 3.282
Fankhauser CD, Wettstein MS, Reinhardt M, Gessendorfer A, Mostafid H, Hermanns T. (2020)
Indications and Complications of Androgen Deprivation Therapy
Semin Oncol Nurs. 36(4):151042
Impact factor: 2.315
Fankhauser CD, Tran B, Pedregal M, Ruiz-Morales JM, Gonzalez-Billalabeitia E, Patrikidou A, Amir E, Seidel C, Bokemeyer C, Hermanns T, Rumyantsev A, Tryakin A, Brito M, Fléchon A, Kwan EM, Cheng T, Castellano D, Del Muro XG, Hamid AA, Ottaviano M, Palmieri G, Kitson R, Reid A, Heng DYC, Bedard PL, Sweeney CJ, Connors JM. (2020)
A Risk-benefit Analysis of Prophylactic Anticoagulation for Patients with Metastatic Germ Cell Tumours Undergoing First-line Chemotherapy
Eur Urol Focus. S2405-4569(20)30280-7
Impact factor: 5.996
Ferraro DA, Lehner F, Becker AS, Kranzbühler B, Kudura K, Mebert I, Messerli M, Hermanns T, Eberli D, Burger IA (2021)
Improved oncological outcome after radical prostatectomy in patients staged with 68 Ga-PSMA-11 PET: a single-center retrospective cohort comparison
Eur J Nucl Med Mol Imaging. 48(4):1219-28
Impact factor: 9.236
Charmpi K, Guo T, Zhong Q, Wagner U, Sun R, Toussaint NC, Fritz CE, Yuan C, Chen H, Rupp NJ, Christiansen A, Rutishauser D, Rüschoff JH, Fankhauser C, Saba K, Poyet C, Hermanns T, Oehl K, Moore AL, Beisel C, Calzone L, Martignetti L, Zhang Q, Zhu Y, Martínez MR, Manica M, Haffner MC, Aebersold R, Wild PJ, Beyer A. (2020)
Convergent network effects along the axis of gene expression during prostate cancer progression
Genome Biol. 2020 Dec 14;21(1):302
Impact factor: 13.583
Kliesch S, Schmidt S, Wilborn D, Aigner C, Albrecht W, Bedke J, Beintker M, Beyersdorff D, Bokemeyer C, Busch J, Classen J, de Wit M, Dieckmann KP, Diemer T, Dieing A, Gockel M, Göckel-Beining B, Hakenberg OW, Heidenreich A, Heinzelbecker J, Herkommer K, Hermanns T, Kaufmann S, Kornmann M, Kotzerke J, Krege S, Kristiansen G, Lorch A, Müller AC, Oechsle K, Ohloff T, Oing C, Otto U, Pfister D, Pichler R, Recken H, Rick O, Rudolph Y, Ruf C, Schirren J, Schmelz H, Schmidberger H, Schrader M, Schweyer S, Seeling S, Souchon R, Winter C, Wittekind C, Zengerling F, Zermann DH, Zillmann R, Albers P (2021)
Management of Germ Cell Tumours of the Testis in Adult Patients. German Clinical Practice Guideline Part I: Epidemiology, Classification, Diagnosis, Prognosis, Fertility Preservation, and Treatment Recommendations for Localized Stages
Urol Int. 105(3-4):169-80
Impact factor: 2.089
Kliesch S, Schmidt S, Wilborn D, Aigner C, Albrecht W, Bedke J, Beintker M, Beyersdorff D, Bokemeyer C, Busch J, Classen J, de Wit M, Dieckmann KP, Diemer T, Dieing A, Gockel M, Göckel-Beining B, Hakenberg OW, Heidenreich A, Heinzelbecker J, Herkommer K, Hermanns T, Kaufmann S, Kornmann M, Kotzerke J, Krege S, Kristiansen G, Lorch A, Müller AC, Oechsle K, Ohloff T, Oing C, Otto U, Pfister D, Pichler R, Recken H, Rick O, Rudolph Y, Ruf C, Schirren J, Schmelz H, Schmidberger H, Schrader M, Schweyer S, Seeling S, Souchon R, Winter C, Wittekind C, Zengerling F, Zermann DH, Zillmann R, Albers P (2021)
Management of Germ Cell Tumours of the Testes in Adult Patients: German Clinical Practice Guideline, PART II - Recommendations for the Treatment of Advanced, Recurrent, and Refractory Disease and Extragonadal and Sex Cord/Stromal Tumours and for the Management of Follow-Up, Toxicity, Quality of Life, Palliative Care, and Supportive Therapy
Urol Int. 105(3-4):181-191
Impact factor: 2.089
Grogg JB, Fronzaroli JN, Oliveira P, Bode PK, Lorch A, Issa A, Beyer J, Eberli D, Sangar V, Hermanns T, Clarke NW, Fankhauser CD (2021)
Clinicopathological characteristics and outcomes in men with mesothelioma of the tunica vaginalis testis: analysis of published case-series data
J Cancer Res Clin Oncol. 2021 Sep;147(9):2671-2679
Impact factor: 4.553
Wettstein MS, David LA, Pazhepurackel C, Qureshi AA, Zisman A, Nesbitt M, Saba K, Herrera-Caceres JO, Fankhauser CD, Ahmad A, Hamilton RJ, Eberli D, Zlotta AR, Sulser T, Fleshner NE, Poyet C, Finelli A, Hermanns T*, Kulkarni GS (2021)
Benefit of a more extended pelvic lymph node dissection among patients undergoing radical prostatectomy for localized prostate cancer: A causal mediation analysis
Prostate. 2021 Apr;81(5):286-294
Impact factor: 4.104
Seidel C, Daugaard G, Nestler T, Tryakin A, Fedyanin M, Fankhauser CD, Hermanns T, Aparicio J, Heinzelbecker J, Paffenholz P, Heidenreich A, De Giorgi U, Cathomas R, Lorch A, Fingerhut A, Gayer F, Bremmer F, Giannatempo P, Necchi A, Raggi D, Aurilio G, Casadei C, Hentrich M, Tran B, Dieckmann KP, Brito M, Ruf C, Mazzocca A, Vincenzi B, Stahl O, Bokemeyer C, Oing C (2021)
The prognostic significance of lactate dehydrogenase levels in seminoma patients with advanced disease: an analysis by the Global Germ Cell Tumor Collaborative Group (G3)
World J Urol. Epub ahead of print
Impact factor: 4.226
Waisbrod S, Natsos A, Wettstein MS, Saba K, Hermanns T, Fankhauser CD, Müller A. (2021)
Assessment of Diagnostic Yield of Cystoscopy and Computed Tomographic Urography for Urinary Tract Cancers in Patients Evaluated for Microhematuria: A Systematic Review and Meta-analysis
JAMA Netw Open. 4(5):e218409.
Impact factor: 8.483
Fankhauser CD, Weber D, Müntener M, Poyet C, Sulser T, Hermanns T (2021)
Effectiveness of Flexible Ureterorenoscopy Versus Extracorporeal Shock Wave Lithotripsy for Renal Calculi of 5-15 mm: Results of a Randomized Controlled Trial
Eur Urol Open Sci. 25:5-10
Impact factor: n/a
Saba K, Högger DC, Hötker AM, Rupp NJ, Sulser T, Hermanns T. (2021)
Dignity of Small Renal Masses: Implications for Diagnostics and Therapy
Praxis (Bern 1994). 110(10):565-570
Impact factor: n/a
Rüschoff JH, Ferraro DA, Muehlematter UJ, Laudicella R, Hermanns T, Rodewald AK, Moch H, Eberli D, Burger IA, Rupp NJ (2021)
What's behind 68Ga-PSMA-11 uptake in primary prostate cancer PET? Investigation of histopathological parameters and immunohistochemical PSMA expression patterns.
Eur J Nucl Med Mol Imaging. Epub ahead of print
Impact factor: 9.236

2. Editorials

Poyet C, Hermanns T (2016)
Prostate cancer risk calculators: still much work ahead.
BJU Int. 118(5):670-671 Impact factor: 5.588
Hermanns T, Poyet C (2017)
The next generation of prostate cancer risk calculators.
Eur Urol. 72(6):897-898
Impact factor: 20.096

3. Case reports

Zeh N, Wild PJ. Bode P, Moch H, Kristiansen G, Sulser T, Hermanns T (2013)
Retroperitoneal teratoma with somatic malignant transformation: A papillary renal cell carcinoma in a germ cell tumour metastasis following platinum-based chemotherapy.
BMC Urol. 13:9
Impact factor: 2.264
Poyet C, Grubhofer F, Zimmermann M, Sulser T, Hermanns T (2013)
Therapy-resistant nephrolithiasis following renal artery coil embolization.
BMC Urol. 13:29
Impact factor: 2.264
Fankhauser CD, Hermanns T, Hasse B, Rancic Z
Excessive wound fluid discharge during retroperitoneal negative pressure wound therapy
Ann Vasc Surg. 43:314.e1-314.e3
Impact factor: 1.466

4. Reviews

Seifert HH, Hermanns T, Sulser T (2008)
GreenLight laser vaporisation of the prostate for treatment of benign prostatic hyperplasia. Development and significance.
Urologe. 47(8): 964-8
Impact factor: 0.639
Fankhauser CD, Kranzbühler B, Poyet C, Hermanns T, Sulser T, Steurer J (2015)
Long-term adverse effects of extracorporeal shock-wave lithotripsy for nephro- and ureterolithiasis: a systematic review.
Urology. 85(5): 991-1006
Impact factor: 2.649
Kozomara M, Hermanns T, Poyet C (2016)
Male Urinary Incontinence – A Taboo Issue.
Praxis. 105(5): 269-77
Impact factor: n/a
Fankhauser CD, Poyet C, Kroeze SGC, Kranzbühler B, Schüler HIG, Guckenberger M, Kaufmann PA, Hermanns T, Burger IA. (2018)
Current and potential future role of PSMA-PET in patients with castration-resistant prostate cancer.
World J Urol. 37(3):457-467
Impact factor: 4.226

5. Book Chapter

Hermanns T, Sulser T
Interventional treatment: Prostate Laser.
Benign prostatic hyperplasia and lower urinary tract symptoms in man, Oxford Urology Library, editors: A. Bachmann & JJMCH de la Rosette, Oxford University Press 2012
Hermanns T, Kuk C, Zlotta AR
Prostate cancer: Clinical Presentation, Diagnosis and Staging.
Urological Oncology, editors: VH Nargund, D Raghavan, HM Sandler Springer Verlag, London 2015

6. Proceedings

Hermanns T, Sulser T, Fatzer M, Baumgartner MK, Rey JM, Sigrist MW, Seifert HH
(2008)
Intra-operative power measurement of laser fibers during photoselective vaporization of the prostate using the 80W-KTP-Greenlight laser.
Proceedings of SPIE, Vol. 6842; Progress in Biomedical Optics and Imaging Vol. 9, No. 1; Photonic Therapeutics and Diagnostics IV, 684211
Hermanns T, Sulser T, Hefermehl LJ, Strebel DD, Michel MS, Müntener M, Meier AH, Seifert HH (2009)
Loss of Power Output and Laser Fibre Degradation during 120 Watt Lithium-Triborate HPS Laser Vaporisation of the Prostate.
Proceedings of SPIE, Vol. 7161; Progress in Biomedical Optics and Imaging Vol. 10, No. 1; Photonic Therapeutics and Diagnostics V, 71611-1
Gross O, Sulser T, Hefermehl LJ, Strebel DD, Largo R, Mortezavi A, Poyet C, Eberli D, Zimmerman M, Müller A, Michel MS, Müntener M, Seifert HH, Hermanns T (2011)
Ablative efficiency of lithium-triborate laser vaporisation and conventional transurethral resection of the prostate: A comparison using transrectal three-dimensional ultrasound volumetry.
Proceedings of SPIE, Vol. 7883; Progress in Biomedical Optics and Imaging Vol. 12, No. 1; Photonic Therapeutics and Diagnostics VII, 78831-1
Kranzbühler B, Gross O, Fankhauser CD, Hefermehl LJ, Poyet C, Largo R, Müntener M, Seifert HH, Zimmermann M, Sulser T, Müller A, Hermanns T (2012)
Tissue ablation after 120W greenlight laser vaporization and bipolar plasma vaporization of the prostate. A comparison using transrectal three-dimensional ultrasound volumetry.
Proceedings of SPIE, Vol. 8207; Progress in Biomedical Optics and Imaging Vol.; Photonic Therapeutics and Diagnostics VIII, 820783-1
Fankhauser CD, Grossmann NC, Beyer J, Hermanns T. (2018)
Re: Sophia C. Kamran, Thomas Seisen, Sarah C. Markt, et al. Contemporary Treatment Patterns and Outcomes for Clinical Stage IS Testicular Cancer. Eur Urol 2018;73:262-70.
Eur Urol. 73(4):e94-e95
Impact factor: 20.096

2003 - 2006	Assistenzarzt, Chirurgie Spital Limmattal
2006 - 2011	Assistenzarzt, Klinik für Urologie, Universitätsspital Zürich und Kantonsspital Aarau
2011 - 2012	Oberarzt, Klinik für Urologie, Universitätsspital Zürich
2012 - 2014	Offizielles Uro-Oncology Fellowship der Society of Urologic Oncology (SUO) in Toronto, Kanada (University Health Network (Princess Margaret Cancer Centre & Toronto General Hospital, Sunnybrook Health Sciences Centre & Odette Cancer Centre, Mount Sinai Hospital & Lunenfeld-Tanenbaum Research Institute))
2014 - 2017	Oberarzt, Klinik für Urologie, Universitätsspital Zürich
2018 - 2022	Leitender Arzt, Klinik für Urologie, Universitätsspital Zürich Leitung des interdisziplinären uroonkologischen Tumorzentrums des Comprehensive Cancer Centers Zürich (CCCZ), des interdiziplinären uroonkologischen Tumorboards und der interdisziplinären uroonkologischen Sprechstunde
Seit 2023	Partner im Zentrum für Urologie Zürich, Klinik Hirslanden und Klinik Im Park

1995 - 2002	Studium der Humanmedizin an der Friedrich-Alexander Universität Erlangen-Nürnberg, der RWTH Aachen und der Universität zu Köln, D
2003	Dissertation, Abschluss mit Auszeichnung (summa cum laude)
2011	Facharzt FMH Urologie
2011	Fellow of the European Board of Urology (FEBU)
2017	Habilitation / Erlangung der Venia Legendi der Universität Zürich
2017	FMH Schwerpunkttitel Operative Urologie